This poster outlines current and future areas of process and analytical development. You will gain insight into our cross-serotype, robust, high yield AAV manufacturing platform. The platform was established with the objective of providing short timelines and a cost-effective scalable process to produce clinical trial and commercial material in up to 2000-liter bioreactors.
